Cargando…

From prescriptions to drug use periods - things to notice

BACKGROUND: Electronic prescription registers provide a vast data source for pharmacoepidemiological research. Prescriptions as such are not suitable for all research purposes; e.g., studying concurrent use of different drugs or adverse drug events during current use. For those purposes, data on dis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanskanen, Antti, Taipale, Heidi, Koponen, Marjaana, Tolppanen, Anna-Maija, Hartikainen, Sirpa, Ahonen, Riitta, Tiihonen, Jari
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239374/ https://www.ncbi.nlm.nih.gov/pubmed/25398553 http://dx.doi.org/10.1186/1756-0500-7-796

Ejemplares similares

From prescription drug purchases to drug use periods – a second generation method (PRE2DUP)
por: Tanskanen, Antti, et al.
Publicado: (2015)

Drug exposure in register-based research—An expert-opinion based evaluation of methods
por: Tanskanen, Antti, et al.
Publicado: (2017)

Antidementia drug use among community-dwelling individuals with Alzheimer’s disease in Finland: a nationwide register-based study
por: Taipale, Heidi, et al.
Publicado: (2014)

Agreement between PRE2DUP register data modeling method and comprehensive drug use interview among older persons
por: Taipale, Heidi, et al.
Publicado: (2016)

Month and Season of Birth as a Risk Factor for Alzheimer’s Disease: A Nationwide Nested Case-control Study
por: Tolppanen, Anna-Maija, et al.
Publicado: (2016)

Antiepileptic Drug Use Is Associated with an Increased Risk of Pneumonia Among Community-Dwelling Persons with Alzheimer’s Disease-Matched Cohort Study
por: Taipale, Heidi, et al.
Publicado: (2019)

Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer’s disease research – the Medication use among persons with Alzheimer’s disease (MEDALZ-2005) study
por: Tolppanen, Anna-Maija, et al.
Publicado: (2013)

Cohort profile: the Finnish Medication and Alzheimer's disease (MEDALZ) study
por: Tolppanen, Anna-Maija, et al.
Publicado: (2016)

Length of Hospital Stay for Hip Fracture and 30-Day Mortality in People With Alzheimer’s Disease: A Cohort Study in Finland
por: Lavikainen, Piia, et al.
Publicado: (2020)

Systemic Estrogen Use and Discontinuation After Alzheimer’s Disease Diagnosis in Finland 2005–2012: A Nationwide Exposure-Matched Cohort Study
por: Tolppanen, Anna-Maija, et al.
Publicado: (2018)

Hip Fracture Risk in Antiepileptic Drug Initiators and Non-Initiators with Alzheimer’s Disease
por: Pisa, Federica, et al.
Publicado: (2021)

Regional changes in psychotropic use among Finnish persons with newly diagnosed Alzheimer’s disease in 2005-2011
por: Tolppanen, Anna-Maija, et al.
Publicado: (2017)

Risk of head and traumatic brain injuries associated with antidepressant use among community-dwelling persons with Alzheimer’s disease: a nationwide matched cohort study
por: Taipale, Heidi, et al.
Publicado: (2017)

Automated multi-dose dispensing in persons with and without Alzheimer’s disease—impacts on pharmacotherapy
por: Vallius, Sanna, et al.
Publicado: (2021)

Causes of death in a nationwide cohort of community-dwellers with Alzheimer’s disease
por: Tolppanen, Anna-Maija, et al.
Publicado: (2020)

Comparison of predictors of hip fracture and mortality after hip fracture in community-dwellers with and without Alzheimer’s disease – exposure-matched cohort study
por: Tolppanen, Anna-Maija, et al.
Publicado: (2016)

Antiepileptic drug use and mortality among community-dwelling persons with Alzheimer disease
por: Sarycheva, Tatyana, et al.
Publicado: (2020)

Antiepileptic Drug Use and the Risk of Stroke Among Community‐Dwelling People With Alzheimer Disease: A Matched Cohort Study
por: Sarycheva, Tatyana, et al.
Publicado: (2018)

Prevalence of oral anticoagulant use among people with and without Alzheimer’s disease
por: Ali Babar, Barkat, et al.
Publicado: (2022)

Changes in the use of diabetes drugs among community-dwelling people with Alzheimer’s disease
por: López-Rubio, Carlos, et al.
Publicado: (2021)

Incidence and Prevalence of Antiepileptic Medication Use in Community-Dwelling Persons with and without Alzheimer’s Disease
por: Sarycheva, Tatyana, et al.
Publicado: (2018)

Opioid Use After Hospital Care due to Hip Fracture Among Community-Dwelling Persons With and Without Alzheimer’s Disease
por: Lintula, Eveliina, et al.
Publicado: (2019)

Incidence and Duration of Cumulative Bisphosphonate Use among Community-Dwelling Persons with or without Alzheimer’s Disease
por: Tiihonen, Miia, et al.
Publicado: (2016)

β2-Adrenoceptor Agonists in Asthma or Chronic Obstructive Pulmonary Disease and Risk of Parkinson’s Disease: Nested Case-Control Study
por: Paakinaho, Anne, et al.
Publicado: (2023)

Disease-Modifying Antirheumatic Drugs and Risk of Parkinson Disease: Nested Case-Control Study of People With Rheumatoid Arthritis
por: Paakinaho, Anne, et al.
Publicado: (2022)

Coronary Revascularization and Postoperative Outcomes in People With and Without Alzheimer’s Disease
por: Vu, Mai, et al.
Publicado: (2021)

Real-world effectiveness of antidepressant use in persons with schizophrenia: within-individual study of 61,889 subjects
por: Puranen, Arto, et al.
Publicado: (2023)

Impact of High Risk Drug Use on Hospitalization and Mortality in Older People with and without Alzheimer’s Disease: A National Population Cohort Study
por: Gnjidic, Danijela, et al.
Publicado: (2014)

Association between different diabetes medication classes and risk of Parkinson's disease in people with diabetes
por: Sunnarborg, Katriina, et al.
Publicado: (2022)

Incidence of antidepressant use among community dwellers with and without Parkinson’s disease – a nationwide cohort study
por: Hentilä, Eerik, et al.
Publicado: (2021)

Identification of Drugs Associated with Lower Risk of Parkinson’s Disease Using a Systematic Screening Approach in a Nationwide Nested Case–Control Study
por: Koponen, Marjaana, et al.
Publicado: (2022)

Length of hospital stay after hip fracture and readmission rates of persons with and without Alzheimer’s disease: a matched cohort study
por: Rajamaki, Blair, et al.
Publicado: (2020)

Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia—A Nationwide Study With 20-Year Follow-up
por: Taipale, Heidi, et al.
Publicado: (2018)

Long-term thiazide use and risk of low-energy fractures among persons with Alzheimer’s disease—nested case-control study
por: Taipale, H., et al.
Publicado: (2019)

Medication Use and Health Care Utilization After a Cost-sharing Increase in Schizophrenia: A Nationwide Analysis
por: Hamina, Aleksi, et al.
Publicado: (2020)

Statin discontinuation in persons with and without Alzheimer’s disease
por: Vu, Mai, et al.
Publicado: (2022)

Recent hospitalization and risk of antidepressant initiation in people with Parkinson’s disease
por: Hämäläinen, Iida, et al.
Publicado: (2022)

Adenosine modulators and calcium channel blockers as add-on treatment for schizophrenia
por: Lintunen, Jonne, et al.
Publicado: (2021)

Primary Nonadherence to Antipsychotic Treatment Among Persons with Schizophrenia
por: Lieslehto, Johannes, et al.
Publicado: (2022)

In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine
por: Luykx, Jurjen J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_is2941ci88pbehqsahulrv76kh